» Sign in / Register

5-Azacytidine

Inhibitor of DNA Methyltransferases

5-AzaC

5-Aza-CR

Ladakamycin, Mylosar, Vidaza

Cat. No. Amount Price (EUR) Buy / Note
NU-961 5 mg 96,43 Add to Basket/Quote Add to Notepad
Structural formula of 5-Azacytidine (Inhibitor of DNA Methyltransferases, 5-AzaC)
Structural formula of 5-Azacytidine

For research use only!

Shipping: shipped on blue ice

Storage Conditions: store at -20 °C

Shelf Life: 12 months after date of delivery

Molecular Formula: C8H12N4O5

Molecular Weight: 244.20 g/mol

CAS#: 320-67-2

EC number: 206-280-2

Purity: ≥ 95 % (HPLC)

Form: white to off-white solid

Applications:
For research use only!

Description:
5-Azacytidine is an inhibitor of DNA-methyltransferases that causes DNA-demethylation or hemi-demethylation. It regulates gene activation and silencing by creating openings that allow transcription factors to bind to DNA and thus for instance to reactivate tumor suppressor genes. 5-Azacytidine is a prodrug, which needs to be phosphorylated by cellular cytidine kinases. Resulting 5-Aza-dCTP is incorporated into DNA and traps the DNA methyltransferase in the progressing fork. 5-Azacytidine is used in treatment of several cancer diseases. IC50 = 2.4 to 2.6 μM for in vitro anti-myeloma activity (myelodysplastic syndrome) and 0.4 μM for inhibiting proliferation of various cancer cell lines.

Related products: Jena Bioscience offers additional inhibitors for DNA-methyltransferases: 5-Aza-2'dCTP (#NU-1118), 5-Azacytosine (#NU-960), 6-Thioguanine (#NU-962) and 6-Mercaptopurine (#NU-963). See also 5-Methyl-CTP and derivatives: #NU-1138, #N-1070, #NU-932, #NU-1125, #NU-1069 and #NU-1067.

Selected References:
Nebbioso (2015) Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. Expert Opinion in Therapeutic Targets 19:1187.
Pantazi et al. (2015) DNA methylation: its role in transcriptional regulation and association with lung cancer. Rep.in Biochem. 5:11.
Ebert et al. (2012) TFAP2E-DKK4 and chemoresistance in colorectal cancer. N. Engl. L. Med. 366:44.
Goel et al. (2012) Epigenetics in colorectal cancer. Gastroenterology 143:1442.
Lyko et al. (2010) The Honey bee epigenomes: Differential methylation of brain DNA in queens and workers. PLoS Biol. 8 (11):e1000505.
Niehrs (2009) Active DNA demethylation and DNA repair. Differentiation 77:1.
Steele et al. (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. British J. Cancer 100:758.
Szyf (2009). Epigenetics, DNA methylation and chromatin: Modifying drugs. Ann. Rev. Pharmacol. Toxicol. 49:243.
Escher et al. (2005) Demethylation using the epigenetic modifier 5-azacytidine, increases the efficiency of transient transfection of macrophages. J. Lipid Res. 46:356.
Holliday et al. (2002) DNA methylation and epigenetic inheritance. Methods 27:179.